Biomarin Pharmaceutical (BMRN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Biomarin Pharmaceutical (BMRN) do?
Biomarin Pharmaceutical Inc (BMRN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops and sells commercial biologics to treat rare genetic metabolic disorders and achondroplasia. Manufactures enzyme replacement and genetic therapies targeting rare diseases caused by specific metabolic gene. It is worth $11.90B on the market and sold $3.69B over the last year.
- Market cap
- $11.90B
- P/E ratio
- None (reported a loss)
- Annual sales
- $3.69B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 19, 2026
Brands and businesses behind BMRN
- Voxzogo: This daily injection increases linear growth in children with achondroplasia and generates revenue via global prescription sales.
- Vimizim: This enzyme replacement therapy treats Morquio A syndrome and earns income from chronic hospital infusions.
- Naglazyme: This enzyme replacement therapy treats MPS VI disease through recurring bi-weekly patient infusions.
- Palynziq: This self-administered daily enzyme injection treats phenylketonuria in adults and earns money via pharmacy sales.
- Roctavian: This one-time gene therapy treats severe hemophilia A and earns revenue through single-dose patient treatments.
- Brineura: This enzyme infusion treats late infantile neuronal ceroid lipofuscinosis type 2 and earns revenue from specialized treatment centers.
BMRN’s flags, in plain English
Each flag is a number from Biomarin Pharmaceutical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.
Wide Gross Margin
Gross margin of 71.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Stupid Cash
Can pay this year's bills 2.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Burning Cash
Losing money, profit margin of -0.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag open with the free trial. Try it free for 7 days.
Questions about BMRN
How big is Biomarin Pharmaceutical?
Biomarin Pharmaceutical’s market cap is $11.90B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.69B: what customers paid the company over the last year, before any costs.
What is BMRN’s P/E ratio?
BMRN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with BMRN?
The business relies heavily on Voxzogo for ongoing sales expansion while competing pharmaceutical firms develop rival achondroplasia therapies. That is one risk on Biomarin Pharmaceutical’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Biomarin Pharmaceutical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BMRN’s filings on SEC.gov. The Margin Monkey is research, not advice.
